Last updated on November 2018

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation


Brief description of study

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

Clinical Study Identifier: NCT03456726

Contact Investigators or Research Sites near you

Start Over

Customer Joy Department. EJ

1013 Eisai Trial Site
Osakasayama, Japan
  Connect »